Silence Therapeutics plc (NASDAQ:SLN) Receives $57.20 Average Price Target from Analysts

Shares of Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) have been assigned a consensus rating of "Buy" from the six ratings firms that are currently covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $57.20.

Several equities research analysts have weighed in on SLN shares. HC Wainwright reiterated a "buy" rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Monday, December 9th. BMO Capital Markets reissued an "outperform" rating on shares of Silence Therapeutics in a research report on Monday, December 2nd. Morgan Stanley reaffirmed an "overweight" rating and issued a $49.00 price target on shares of Silence Therapeutics in a research report on Tuesday, October 8th. William Blair reiterated an "outperform" rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. Finally, Chardan Capital reissued a "buy" rating and issued a $55.00 price objective on shares of Silence Therapeutics in a research note on Tuesday, December 10th.

Institutional Investors Weigh In On Silence Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Nicholas Investment Partners LP purchased a new position in shares of Silence Therapeutics in the 2nd quarter valued at about $2,859,000. First Turn Management LLC acquired a new stake in Silence Therapeutics in the second quarter valued at approximately $10,209,000. Lombard Odier Asset Management USA Corp increased its position in shares of Silence Therapeutics by 0.7% in the second quarter. Lombard Odier Asset Management USA Corp now owns 2,405,998 shares of the company's stock valued at $45,714,000 after buying an additional 17,086 shares in the last quarter. Marshall Wace LLP raised its stake in shares of Silence Therapeutics by 7.3% during the 2nd quarter. Marshall Wace LLP now owns 149,397 shares of the company's stock worth $2,839,000 after buying an additional 10,206 shares during the period. Finally, Millennium Management LLC lifted its position in shares of Silence Therapeutics by 91.2% during the 2nd quarter. Millennium Management LLC now owns 782,941 shares of the company's stock valued at $14,876,000 after buying an additional 373,523 shares in the last quarter. Institutional investors and hedge funds own 98.73% of the company's stock.

Silence Therapeutics Trading Down 5.7 %

Shares of NASDAQ SLN traded down $0.38 during trading hours on Wednesday, reaching $6.34. The stock had a trading volume of 167,229 shares, compared to its average volume of 221,706. Silence Therapeutics has a 52-week low of $5.81 and a 52-week high of $27.72. The firm has a market cap of $189.74 million, a price-to-earnings ratio of -4.04 and a beta of 1.08. The business's fifty day moving average price is $9.74 and its two-hundred day moving average price is $15.50.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.